Anacor Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference

  Anacor Pharmaceuticals to Present at the Piper Jaffray 24th Annual
  Healthcare Conference

Piper Jaffray Healthcare Conference 2012

Business Wire

PALO ALTO, Calif. -- November 13, 2012

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the
company’s Chief Executive Officer, will be participating in the Piper Jaffray
24^th Annual Healthcare Conference on Wednesday, November 28, 2012 at 11:30
a.m. ET in New York, New York.

The event will be webcast live and may be accessed under “Events and
Presentations” on the Investors page of Anacor’s website at www.anacor.com. A
replay will also be available for three months following the presentation.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered seven compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, a topical antifungal for the treatment of
onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other clinical product candidates —
AN2718 and AN2898, which are backup compounds to tavaborole and AN2728,
respectively, and AN3365 (formerly known as GSK2251052, or GSK‘052), a
systemic antibiotic for the treatment of infections caused by Gram-negative
bacteria, which previously was licensed to GlaxoSmithKlineLLC, or GSK. GSK
will be returning all rights to the compound to us and we are considering our
options for further development, if any, of this compound. We have discovered
two other compounds that we have out-licensed for further development —
AN8194, a compound for the treatment of an animal health indication that is
licensed to Eli Lilly and Company, or Lilly, and AN5568, also referred to as
SCYX-7158, for human African trypanosomiasis (HAT, or sleeping sickness),
which is licensed to Drugs for Neglected Diseases initiative, or DNDi. We also
have a pipeline of other internally discovered topical and systemic
boron-based compounds in development. For more information, visit
http://www.anacor.com.

Contact:

Anacor Pharmaceuticals
Director, Investor Relations and Corporate Communications
DeDe Sheel, 650-543-7575
 
Press spacebar to pause and continue. Press esc to stop.